A detailed history of Candriam S.C.A. transactions in United Therapeutics Corp stock. As of the latest transaction made, Candriam S.C.A. holds 67,148 shares of UTHR stock, worth $25.9 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
67,148
Previous 64,513 4.08%
Holding current value
$25.9 Million
Previous $20.6 Million 17.09%
% of portfolio
0.14%
Previous 0.13%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$311.04 - $363.55 $819,590 - $957,954
2,635 Added 4.08%
67,148 $24.1 Million
Q2 2024

Aug 05, 2024

BUY
$228.26 - $319.04 $14.1 Million - $19.6 Million
61,573 Added 2094.32%
64,513 $20.6 Million
Q1 2024

May 03, 2024

SELL
$210.76 - $249.51 $91,259 - $108,037
-433 Reduced 12.84%
2,940 $675,000
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $83,588 - $99,949
389 Added 13.04%
3,373 $741,000
Q2 2023

Aug 08, 2023

SELL
$205.19 - $232.99 $943,258 - $1.07 Million
-4,597 Reduced 60.64%
2,984 $658,000
Q1 2023

May 12, 2023

BUY
$212.99 - $276.17 $1.61 Million - $2.09 Million
7,581 New
7,581 $1.7 Million
Q4 2018

Feb 14, 2019

SELL
$101.4 - $128.73 $283,920 - $360,444
-2,800 Closed
0 $0
Q3 2018

Nov 07, 2018

BUY
$113.81 - $129.46 $318,668 - $362,488
2,800 New
2,800 $358,000
Q2 2018

Aug 14, 2018

SELL
$101.14 - $118.31 $418,921 - $490,040
-4,142 Closed
0 $0
Q4 2017

Feb 07, 2018

BUY
$118.58 - $151.28 $227,555 - $290,306
1,919 Added 86.32%
4,142 $613,000
Q3 2017

Nov 03, 2017

BUY
$114.6 - $136.81 $254,755 - $304,128
2,223
2,223 $261,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.